Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, Optical Coherence | 20 | 2021 | 42 | 4.850 |
Why?
|
| Glaucoma | 9 | 2020 | 11 | 3.200 |
Why?
|
| Optic Nerve Diseases | 6 | 2020 | 12 | 2.980 |
Why?
|
| Glaucoma, Open-Angle | 6 | 2020 | 17 | 2.630 |
Why?
|
| Intraocular Pressure | 11 | 2020 | 25 | 2.530 |
Why?
|
| Retinal Ganglion Cells | 12 | 2020 | 16 | 2.520 |
Why?
|
| Nerve Fibers | 12 | 2020 | 30 | 2.220 |
Why?
|
| Optic Disk | 4 | 2020 | 6 | 2.210 |
Why?
|
| Visual Acuity | 9 | 2020 | 66 | 2.200 |
Why?
|
| Visual Fields | 12 | 2020 | 25 | 1.720 |
Why?
|
| Algorithms | 6 | 2020 | 463 | 1.460 |
Why?
|
| Vision, Low | 2 | 2018 | 3 | 1.290 |
Why?
|
| Papilledema | 2 | 2018 | 12 | 1.270 |
Why?
|
| Retrospective Studies | 18 | 2020 | 3122 | 1.050 |
Why?
|
| Aged | 27 | 2021 | 9515 | 1.040 |
Why?
|
| Cross-Sectional Studies | 15 | 2021 | 1366 | 1.000 |
Why?
|
| Bruch Membrane | 3 | 2019 | 3 | 0.970 |
Why?
|
| Photography | 3 | 2019 | 33 | 0.880 |
Why?
|
| Humans | 40 | 2021 | 29220 | 0.870 |
Why?
|
| Male | 31 | 2021 | 17876 | 0.870 |
Why?
|
| Fluorescein Angiography | 3 | 2019 | 16 | 0.860 |
Why?
|
| Middle Aged | 26 | 2021 | 10872 | 0.850 |
Why?
|
| Female | 33 | 2021 | 18241 | 0.840 |
Why?
|
| Lasers, Solid-State | 2 | 2019 | 7 | 0.830 |
Why?
|
| Eye Diseases, Hereditary | 2 | 2018 | 2 | 0.800 |
Why?
|
| Macular Degeneration | 2 | 2020 | 21 | 0.800 |
Why?
|
| Retinal Vessels | 4 | 2021 | 18 | 0.740 |
Why?
|
| Aged, 80 and over | 12 | 2020 | 3728 | 0.720 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2019 | 1 | 0.710 |
Why?
|
| Iridectomy | 1 | 2019 | 1 | 0.710 |
Why?
|
| Iris | 1 | 2019 | 6 | 0.710 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2018 | 1 | 0.670 |
Why?
|
| Vitreous Body | 1 | 2018 | 8 | 0.660 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2018 | 2 | 0.650 |
Why?
|
| Phacoemulsification | 1 | 2018 | 3 | 0.650 |
Why?
|
| Endophthalmitis | 1 | 2018 | 4 | 0.650 |
Why?
|
| Ciliary Body | 1 | 2018 | 1 | 0.640 |
Why?
|
| Hydrophthalmos | 1 | 2018 | 1 | 0.640 |
Why?
|
| Microphthalmos | 1 | 2018 | 1 | 0.640 |
Why?
|
| Skin Abnormalities | 1 | 2018 | 1 | 0.640 |
Why?
|
| Color Vision | 1 | 2018 | 1 | 0.640 |
Why?
|
| Night Vision | 1 | 2018 | 1 | 0.640 |
Why?
|
| Ophthalmology | 1 | 2018 | 4 | 0.640 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2018 | 7 | 0.640 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2018 | 18 | 0.640 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2017 | 1 | 0.640 |
Why?
|
| Light | 1 | 2018 | 25 | 0.630 |
Why?
|
| Laser Coagulation | 1 | 2018 | 12 | 0.630 |
Why?
|
| Uveal Neoplasms | 1 | 2018 | 25 | 0.630 |
Why?
|
| Malpractice | 1 | 2018 | 20 | 0.630 |
Why?
|
| Endoscopy | 1 | 2018 | 40 | 0.620 |
Why?
|
| Liability, Legal | 1 | 2018 | 28 | 0.620 |
Why?
|
| Laser Therapy | 1 | 2018 | 52 | 0.620 |
Why?
|
| Tonometry, Ocular | 5 | 2020 | 6 | 0.620 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 74 | 0.610 |
Why?
|
| Epilepsy | 2 | 2014 | 59 | 0.580 |
Why?
|
| Melanoma | 1 | 2018 | 148 | 0.570 |
Why?
|
| Patient Compliance | 2 | 2015 | 212 | 0.570 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 343 | 0.560 |
Why?
|
| Alzheimer Disease | 4 | 2020 | 312 | 0.560 |
Why?
|
| ROC Curve | 4 | 2020 | 149 | 0.540 |
Why?
|
| Eye Diseases | 1 | 2015 | 5 | 0.540 |
Why?
|
| Appointments and Schedules | 1 | 2015 | 16 | 0.530 |
Why?
|
| Appendicitis | 1 | 2015 | 13 | 0.520 |
Why?
|
| Cumulative Trauma Disorders | 1 | 2014 | 14 | 0.500 |
Why?
|
| Sprains and Strains | 1 | 2014 | 10 | 0.500 |
Why?
|
| Microscopy, Acoustic | 3 | 2019 | 3 | 0.500 |
Why?
|
| Mammography | 1 | 2014 | 37 | 0.500 |
Why?
|
| Adult | 12 | 2020 | 8468 | 0.490 |
Why?
|
| Minority Groups | 1 | 2014 | 71 | 0.480 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 98 | 0.470 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 142 | 0.470 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 871 | 0.460 |
Why?
|
| Postoperative Complications | 1 | 2017 | 670 | 0.440 |
Why?
|
| Vision Disorders | 4 | 2020 | 20 | 0.440 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 375 | 0.430 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 153 | 0.430 |
Why?
|
| Fundus Oculi | 4 | 2019 | 11 | 0.420 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 493 | 0.420 |
Why?
|
| Microvessels | 3 | 2021 | 23 | 0.410 |
Why?
|
| Gonioscopy | 3 | 2020 | 3 | 0.400 |
Why?
|
| Choroid | 2 | 2021 | 3 | 0.390 |
Why?
|
| Contrast Sensitivity | 2 | 2020 | 3 | 0.350 |
Why?
|
| Disease Progression | 5 | 2020 | 572 | 0.290 |
Why?
|
| Child | 3 | 2018 | 2221 | 0.280 |
Why?
|
| United States | 4 | 2020 | 3648 | 0.270 |
Why?
|
| Chronic Disease | 2 | 2018 | 370 | 0.260 |
Why?
|
| Area Under Curve | 3 | 2019 | 85 | 0.260 |
Why?
|
| Infant | 2 | 2018 | 973 | 0.230 |
Why?
|
| Angiography | 2 | 2021 | 75 | 0.220 |
Why?
|
| Case-Control Studies | 3 | 2021 | 860 | 0.210 |
Why?
|
| Treatment Outcome | 4 | 2019 | 3108 | 0.210 |
Why?
|
| Adolescent | 4 | 2020 | 3265 | 0.210 |
Why?
|
| Heme Oxygenase-1 | 1 | 2011 | 33 | 0.190 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2011 | 41 | 0.190 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2020 | 8 | 0.190 |
Why?
|
| Autophagy | 1 | 2011 | 53 | 0.190 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 107 | 0.190 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 788 | 0.190 |
Why?
|
| Macula Lutea | 1 | 2020 | 9 | 0.190 |
Why?
|
| Artifacts | 1 | 2020 | 38 | 0.190 |
Why?
|
| Vision Tests | 1 | 2020 | 1 | 0.190 |
Why?
|
| Parkinson Disease | 1 | 2021 | 68 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 49 | 0.180 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2019 | 2 | 0.180 |
Why?
|
| Retinal Neurons | 1 | 2019 | 2 | 0.180 |
Why?
|
| Vitrectomy | 1 | 2019 | 8 | 0.180 |
Why?
|
| Population Surveillance | 1 | 2020 | 119 | 0.180 |
Why?
|
| Geographic Atrophy | 1 | 2019 | 1 | 0.170 |
Why?
|
| Macrophages | 1 | 2011 | 188 | 0.170 |
Why?
|
| Physical Examination | 1 | 2019 | 82 | 0.170 |
Why?
|
| Retinal Degeneration | 1 | 2019 | 14 | 0.170 |
Why?
|
| Arteritis | 1 | 2018 | 1 | 0.170 |
Why?
|
| Registries | 1 | 2020 | 280 | 0.170 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 667 | 0.170 |
Why?
|
| Risk Factors | 2 | 2017 | 3550 | 0.160 |
Why?
|
| Plasmapheresis | 1 | 2018 | 9 | 0.160 |
Why?
|
| Recovery of Function | 1 | 2019 | 190 | 0.160 |
Why?
|
| Vancomycin | 1 | 2018 | 19 | 0.160 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 113 | 0.160 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2018 | 4 | 0.160 |
Why?
|
| Trisomy | 1 | 2018 | 8 | 0.160 |
Why?
|
| Optic Disk Drusen | 1 | 2017 | 1 | 0.160 |
Why?
|
| Chromosomes, Human, X | 1 | 2018 | 12 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 242 | 0.160 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 27 | 0.160 |
Why?
|
| Acute Disease | 1 | 2018 | 239 | 0.160 |
Why?
|
| Medical Errors | 1 | 2018 | 36 | 0.150 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 2114 | 0.150 |
Why?
|
| Time Factors | 2 | 2019 | 2003 | 0.150 |
Why?
|
| Electroencephalography | 2 | 2014 | 71 | 0.150 |
Why?
|
| Signal Transduction | 1 | 2011 | 667 | 0.150 |
Why?
|
| Reoperation | 1 | 2017 | 203 | 0.150 |
Why?
|
| Epidemiology | 1 | 2016 | 5 | 0.140 |
Why?
|
| Cognition | 1 | 2020 | 526 | 0.140 |
Why?
|
| Biostatistics | 1 | 2016 | 8 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2018 | 333 | 0.140 |
Why?
|
| Prevalence | 2 | 2020 | 907 | 0.140 |
Why?
|
| Statistics as Topic | 1 | 2016 | 107 | 0.140 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 69 | 0.140 |
Why?
|
| Lymph Nodes | 1 | 2016 | 92 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 285 | 0.130 |
Why?
|
| Iohexol | 1 | 2015 | 6 | 0.130 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2016 | 84 | 0.130 |
Why?
|
| Colitis, Ischemic | 1 | 2014 | 1 | 0.130 |
Why?
|
| Mesenteric Veins | 1 | 2014 | 5 | 0.130 |
Why?
|
| Marfan Syndrome | 1 | 2014 | 5 | 0.130 |
Why?
|
| Arteriovenous Malformations | 1 | 2014 | 7 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2018 | 307 | 0.130 |
Why?
|
| Mesenteric Arteries | 1 | 2014 | 18 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2021 | 2027 | 0.130 |
Why?
|
| Contrast Media | 1 | 2015 | 124 | 0.120 |
Why?
|
| Young Adult | 3 | 2020 | 2413 | 0.120 |
Why?
|
| Incidence | 1 | 2017 | 1123 | 0.120 |
Why?
|
| Curriculum | 1 | 2016 | 196 | 0.120 |
Why?
|
| Aging | 1 | 2020 | 881 | 0.120 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2013 | 9 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 533 | 0.120 |
Why?
|
| Language | 1 | 2013 | 44 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 64 | 0.110 |
Why?
|
| Brain | 1 | 2019 | 930 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2013 | 114 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 710 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2015 | 1168 | 0.100 |
Why?
|
| Ocular Hypertension | 2 | 2020 | 6 | 0.100 |
Why?
|
| Regional Blood Flow | 2 | 2021 | 82 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2019 | 478 | 0.070 |
Why?
|
| Age Factors | 2 | 2020 | 1110 | 0.060 |
Why?
|
| Fovea Centralis | 1 | 2020 | 1 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 53 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 83 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2020 | 25 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2011 | 183 | 0.050 |
Why?
|
| Autopsy | 1 | 2020 | 37 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2020 | 105 | 0.050 |
Why?
|
| Cytokines | 1 | 2011 | 243 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 213 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2019 | 95 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 726 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 725 | 0.040 |
Why?
|
| Rats | 1 | 2011 | 1604 | 0.040 |
Why?
|
| North Carolina | 1 | 2021 | 1425 | 0.040 |
Why?
|
| Axilla | 1 | 2016 | 15 | 0.040 |
Why?
|
| California | 1 | 2016 | 60 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2016 | 25 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 56 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 175 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2016 | 111 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2016 | 110 | 0.030 |
Why?
|
| Mice | 1 | 2011 | 2372 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 64 | 0.030 |
Why?
|
| Students, Medical | 1 | 2016 | 121 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 1219 | 0.030 |
Why?
|
| Asian Americans | 1 | 2013 | 98 | 0.030 |
Why?
|
| Logistic Models | 1 | 2013 | 729 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 1695 | 0.020 |
Why?
|
| Animals | 1 | 2011 | 7302 | 0.020 |
Why?
|
| Hispanic Americans | 1 | 2013 | 904 | 0.020 |
Why?
|
| African Americans | 1 | 2013 | 1373 | 0.020 |
Why?
|